Hank Mansbach
2021
In 2021, Hank Mansbach earned a total compensation of $2M as Chief Medical Officer at 89bio, a 14% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $158,400 |
---|---|
Option Awards | $1,123,828 |
Salary | $440,000 |
Stock Awards | $230,100 |
Other | $4,816 |
Total | $1,957,144 |
Mansbach received $1.1M in option awards, accounting for 57% of the total pay in 2021.
Mansbach also received $158.4K in non-equity incentive plan, $440K in salary, $230.1K in stock awards and $4.8K in other compensation.
Rankings
In 2021, Hank Mansbach's compensation ranked 6,124th out of 12,415 executives tracked by ExecPay. In other words, Mansbach earned more than 50.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,124 out of 12,415 | 51st |
Division Manufacturing | 2,594 out of 5,508 | 53rd |
Major group Chemicals And Allied Products | 1,131 out of 2,378 | 52nd |
Industry group Drugs | 1,006 out of 2,099 | 52nd |
Industry Pharmaceutical Preparations | 727 out of 1,549 | 53rd |
Source: SEC filing on April 14, 2022.
Mansbach's colleagues
We found two more compensation records of executives who worked with Hank Mansbach at 89bio in 2021.
News
89bio CEO Rohan Palekar's 2023 pay jumps 79% to $5.6M
April 17, 2024
89bio CEO Rohan Palekar's 2022 pay falls 36% to $3.1M
April 24, 2023
89bio CEO Rohan Palekar's 2021 pay rises 1% to $4.9M
April 14, 2022
89bio CEO Rohan Palekar's 2020 pay jumps 378% to $4.9M
April 15, 2021
89bio CEO Rohan Palekar's 2019 pay jumps 44% to $1M
May 8, 2020